Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET^® in Japan

Yusuke Okadaa Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan;b Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, JapanView further author information

Kazuhiro Kajiyamaa Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan;b Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan;c Office of Regulatory Science Research, Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, JapanView further author information

Chieko Ishigurod Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, JapanView further author information

Takahiro Nonakad Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, JapanView further author information

Tomomi Komakia Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, JapanView further author information

Wataru Kugaa Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, JapanView further author information

Noriyuki Komiyamaa Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, JapanView further author information

Toyotaka Iguchia Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, JapanView further author information

Naoya Horiuchib Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, JapanView further author information

Yoshiaki Uyamad Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan;e Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, JapanCorrespondence[email protected]

https://orcid.org/0000-0002-0430-9887 View further author information

show all

Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET^® in Japan

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET® in Japan

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET^® in Japan